At Achillion, we are driven to transform the lives of patients and families affected by diseases of the complement system, an integral part of the innate immune system. Scientific and clinical evidence has implicated the complement system, and specifically the complement Alternative Pathway (AP), in numerous devastating diseases and conditions. Our principal focus at Achillion is to advance our clinical-stage portfolio of orally administered factor D inhibitors into late-stage development and potential commercialization for patients with devastating disorders of the AP. Source
No articles found.
Enochian Biosciences is a pre-clinical stage biotechnology company committed to us...
Enochian Biosciences is a pre-clinical stage bi...
Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing ...
Trillium Therapeutics Inc. is a clinical stage ...
Voyager Therapeutics is developing life-changing gene therapies for fatal and debi...
Voyager Therapeutics is developing life-changin...
Organogenesis Holdings Inc. is a leading regenerative medicine company focused on ...
Organogenesis Holdings Inc. is a leading regene...
Join the National Investor Network and get the latest information with your interests in mind.